ReviewPharmaceutical research2008
Immune cell recruitment and cell-based system for cancer therapy.
Review in Pharmaceutical research, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 40 citations in OpenAlex.
- Optogenetic engineering for precision cancer immunotherapy.Trends in pharmacological sciences · 2025Review
- Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer.Cancers · 2022Review
- Recent Developments in the Study of the Microenvironment of Cancer and Drug Delivery.Current drug metabolism · 2022Article
- Mathematical model of a personalized neoantigen cancer vaccine and the human immune system.PLoS computational biology · 2021Article
- Inhibition of WHSC1 Allows for Reprogramming of the Immune Compartment in Prostate Cancer.International journal of molecular sciences · 2021Article
- Biohybrid Nanosystems for Cancer Treatment: Merging the Best of Two Worlds.Advances in experimental medicine and biology · 2021Article
- Review
- In vivo cell tracking with bioluminescence imaging.Nuclear medicine and molecular imaging · 2015Review
- Optogenetic control of chemokine receptor signal and T-cell migration.Proceedings of the National Academy of Sciences of the United States of America · 2014Article
- [Influence of anesthesia procedure on malignant tumor outcome].Der Anaesthesist · 2012Review
- Effect of fractalkine-Fc delivery in experimental lung metastasis using DNA/704 nanospheres.Cancer gene therapy · 2011Article
- In vivo bioluminescent imaging (BLI): noninvasive visualization and interrogation of biological processes in living animals.Sensors (Basel, Switzerland) · 2011Review
- Article
- Non-invasive cell tracking in cancer and cancer therapy.Current topics in medicinal chemistry · 2010Review
- Immunotherapy of human cancers using gene modified T lymphocytes.Current gene therapy · 2009Review
- Soluble MHC-peptide complexes: tools for the monitoring of T cell responses in clinical trials and basic research.Cancer immunity · 2009Article
- NK cells are migrated and indispensable in the anti-tumor activity induced by CCL27 gene therapy.Cancer immunology, immunotherapy : CII · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune cells, such as cytotoxic T lymphocytes, natural killer cells, B cells, and dendritic cells, have a central role in cancer immunotherapy. Conventional studies of cancer immunotherapy have focused mainly on the search for an efficient means to prime/activate tumor-associated antigen-specific immunity. A systematic understanding of the molecular basis of the trafficking and biodistribution of immune cells, however, is important for the development of more efficacious cancer immunotherapies. It is well established that the basis and premise of immunotherapy is the accumulation of effective immune cells in tumor tissues. Therefore, it is crucial to control the distribution of immune cells to optimize cancer immunotherapy. Recent characterization of various chemokines and chemokine receptors in the immune system has increased our knowledge of the regulatory mechanisms of the immune response and tolerance based on immune cell localization. Here, we review the immune cell recruitment and cell-based systems that can potentially control the systemic pharmacokinetics of immune cells and, in particular, focus on cell migrating molecules, i.e., chemokines, and their receptors, and their use in cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.